HALT-D: a randomized open-label phase II study of crofelemer for the prevention of chemotherapy-induced diarrhea in patients with HER2-positive breast cancer receiving trastuzumab, pertuzumab, and a taxane.
Saved in:
| Title: | HALT-D: a randomized open-label phase II study of crofelemer for the prevention of chemotherapy-induced diarrhea in patients with HER2-positive breast cancer receiving trastuzumab, pertuzumab, and a taxane. |
|---|---|
| Authors: | Pohlmann PR; Georgetown Lombardi Comprehensive Cancer Center, Washington, DC, USA.; MedStar Georgetown University Hospital, Washington, DC, USA.; Department of Breast Medical Oncology, University of Texas MD Anderson Cancer Center, Houston, TX, USA., Graham D; Georgetown Lombardi Comprehensive Cancer Center, Washington, DC, USA.; Hackensack University Medical Center, Hackensack, NJ, USA., Wu T; Georgetown Lombardi Comprehensive Cancer Center, Washington, DC, USA.; Clinical Research Management Office, Georgetown University Medical Center, Washington, DC, USA., Ottaviano Y; Medstar Franklin Square Medical Center, Baltimore, MD, USA., Mohebtash M; Medstar Franklin Square Medical Center, Baltimore, MD, USA., Kurian S; Medstar Franklin Square Medical Center, Baltimore, MD, USA., McNamara D; Georgetown Lombardi Comprehensive Cancer Center, Washington, DC, USA.; Hackensack University Medical Center, Hackensack, NJ, USA., Lynce F; Dana-Farber Cancer Institute, Boston, MA, USA., Warren R; Georgetown Lombardi Comprehensive Cancer Center, Washington, DC, USA.; MedStar Georgetown University Hospital, Washington, DC, USA.; Clinical Research Management Office, Georgetown University Medical Center, Washington, DC, USA., Dilawari A; Georgetown Lombardi Comprehensive Cancer Center, Washington, DC, USA.; MedStar Georgetown University Hospital, Washington, DC, USA.; Clinical Research Management Office, Georgetown University Medical Center, Washington, DC, USA.; FDA Center for Drug Evaluation and Research, Silver Spring, MD, USA., Rao S; Medstar Franklin Square Medical Center, Baltimore, MD, USA., Mainor C; Georgetown Lombardi Comprehensive Cancer Center, Washington, DC, USA.; MedStar Georgetown University Hospital, Washington, DC, USA.; Clinical Research Management Office, Georgetown University Medical Center, Washington, DC, USA., Swanson N; Clinical Research Management Office, Georgetown University Medical Center, Washington, DC, USA., Tan M; Georgetown Lombardi Comprehensive Cancer Center, Washington, DC, USA.; Clinical Research Management Office, Georgetown University Medical Center, Washington, DC, USA.; Department of Biostatistics, Bioinformatics, and Biomathematics, Georgetown University Medical Center, Washington, DC, USA., Isaacs C; Georgetown Lombardi Comprehensive Cancer Center, Washington, DC, USA.; Clinical Research Management Office, Georgetown University Medical Center, Washington, DC, USA., Swain SM; Georgetown Lombardi Comprehensive Cancer Center, Washington, DC, USA. sandra.swain@georgetown.edu.; MedStar Health, Washington, DC, USA. sandra.swain@georgetown.edu. |
| Source: | Breast cancer research and treatment [Breast Cancer Res Treat] 2022 Dec; Vol. 196 (3), pp. 571-581. Date of Electronic Publication: 2022 Oct 25. |
| Publication Type: | Randomized Controlled Trial; Clinical Trial, Phase II; Journal Article |
| Journal Info: | Publisher: Kluwer Academic Country of Publication: Netherlands NLM ID: 8111104 Publication Model: Print-Electronic Cited Medium: Internet ISSN: 1573-7217 (Electronic) Linking ISSN: 01676806 NLM ISO Abbreviation: Breast Cancer Res Treat Subsets: MEDLINE |
| Database: | MEDLINE Ultimate |
|
Full text is not displayed to guests.
Login for full access.
|
|
| ISSN: | 1573-7217 |
|---|---|
| DOI: | 10.1007/s10549-022-06743-9 |
